With preapproval information exchange (PIE) serving as a critical entry point into the broader Market Access journey, the initial conversation between manufacturers and payers can shape payer perceptions, planning assumptions, and ultimately coverage decisions well before a product reaches the market.
To reveal what truly drives value in these early engagements, Precision AQ conducted a single-blinded survey of 23 current access decision-makers, including medical and pharmacy directors from national plans, regional plans, pharmacy benefit managers (PBMs), and health systems.
Not only did the findings reveal clear payer preferences across content, timing, and format, but they also exposed key pitfalls that can undermine an otherwise strong PIE engagement. The data further point to how priorities shift across launch scenarios, from rare disease and oncology to cell and gene therapy and competitive classes, challenging manufacturers to rethink a one-size-fits-all approach.
Download the full report to see the complete findings and build a PIE strategy that sets your launch up for success.
